Institution
University of Bordeaux
Education•Bordeaux, France•
About: University of Bordeaux is a education organization based out in Bordeaux, France. It is known for research contribution in the topics: Population & Laser. The organization has 28811 authors who have published 55536 publications receiving 1619635 citations. The organization is also known as: UB.
Topics: Population, Laser, Raman spectroscopy, Polymerization, Crystal structure
Papers published on a yearly basis
Papers
More filters
••
386 citations
••
Heidelberg University1, French Institute of Health and Medical Research2, University Hospital of North Norway3, Instituto Português de Oncologia Francisco Gentil4, VU University Medical Center5, Masaryk University6, University of Helsinki7, National and Kapodistrian University of Athens8, Complutense University of Madrid9, Versailles Saint-Quentin-en-Yvelines University10, Odense University Hospital11, Lund University12, University of Auvergne13, Ludwig Maximilian University of Munich14, University of Bordeaux15
TL;DR: In this paper, a prospective, non-randomised trial was conducted at 61 European centres in 11 countries to investigate the impact of stopping TKI therapy on the survival of patients with chronic myeloid leukaemia.
Abstract: Background: Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a prerequisite for TKI therapy discontinuation. We aimed to define precise conditions for stopping treatment. Methods: In this prospective, non-randomised trial, we enrolled patients with chronic myeloid leukaemia at 61 European centres in 11 countries. Eligible patients had chronic-phase chronic myeloid leukaemia, had received any TKI for at least 3 years (without treatment failure according to European LeukemiaNet [ELN] recommendations), and had a confirmed deep molecular response for at least 1 year. The primary endpoint was molecular relapse-free survival, defined by loss of major molecular response (MMR; >0·1% BCR-ABL1 on the International Scale) and assessed in all patients with at least one molecular result. Secondary endpoints were a prognostic analysis of factors affecting maintenance of MMR at 6 months in learning and validation samples and the cost impact of stopping TKI therapy. We considered loss of haematological response, progress to accelerated-phase chronic myeloid leukaemia, or blast crisis as serious adverse events. This study presents the results of the prespecified interim analysis, which was done after the 6-month molecular relapse-free survival status was known for 200 patients. The study is ongoing and is registered with ClinicalTrials.gov, number NCT01596114. Findings: Between May 30, 2012, and Dec 3, 2014, we assessed 868 patients with chronic myeloid leukaemia for eligibility, of whom 758 were enrolled. Median follow-up of the 755 patients evaluable for molecular response was 27 months (IQR 21–34). Molecular relapse-free survival for these patients was 61% (95% CI 57–64) at 6 months and 50% (46–54) at 24 months. Of these 755 patients, 371 (49%) lost MMR after TKI discontinuation, four (1%) died while in MMR for reasons unrelated to chronic myeloid leukaemia (myocardial infarction, lung cancer, renal cancer, and heart failure), and 13 (2%) restarted TKI therapy while in MMR. A further six (1%) patients died in chronic-phase chronic myeloid leukaemia after loss of MMR and re-initiation of TKI therapy for reasons unrelated to chronic myeloid leukaemia, and two (<1%) patients lost MMR despite restarting TKI therapy. In the prognostic analysis in 405 patients who received imatinib as first-line treatment (learning sample), longer treatment duration (odds ratio [OR] per year 1·14 [95% CI 1·05–1·23]; p=0·0010) and longer deep molecular response durations (1·13 [1·04–1·23]; p=0·0032) were associated with increasing probability of MMR maintenance at 6 months. The OR for deep molecular response duration was replicated in the validation sample consisting of 171 patients treated with any TKI as first-line treatment, although the association was not significant (1·13 [0·98–1·29]; p=0·08). TKI discontinuation was associated with substantial cost savings (an estimated €22 million). No serious adverse events were reported. Interpretation: Patients with chronic myeloid leukaemia who have achieved deep molecular responses have good molecular relapse-free survival. Such patients should be considered for TKI discontinuation, particularly those who have been in deep molecular response for a long time. Stopping treatment could spare patients from treatment-induced side-effects and reduce health expenditure. Funding: ELN Foundation and France National Cancer Institute.
385 citations
••
TL;DR: In this article, high resolution pollen, dinocyst and isotopic data for the Last Interglacial complex from marine core MD952042 (southwestern margin of the Iberian Peninsula; 37°48′N; 10°10′W; 3148 m) were presented.
385 citations
••
University of Newcastle1, University of Melbourne2, University of Chicago3, University of Calgary4, Complutense University of Madrid5, University of Bordeaux6, Virginia Commonwealth University7, Mayo Clinic8, Johns Hopkins University9, University of Udine10, University of Regensburg11, University of St. Gallen12, University of Washington13, University of Bern14, University of Sydney15
TL;DR: Among premenopausal women with breast cancer, the addition of ovarian suppression to tamoxifen resulted in significantly higher 8‐year rates of both disease‐free and overall survival than tamox ifen alone and the use of exemestane plus ovarian suppression resulted in even higher rates of freedom from recurrence.
Abstract: Background In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT), the 5-year rates of recurrence of breast cancer were significantly lower among premenopausal women who received the aromatase inhibitor exemestane plus ovarian suppression than among those who received tamoxifen plus ovarian suppression. The addition of ovarian suppression to tamoxifen did not result in significantly lower recurrence rates than those with tamoxifen alone. Here, we report the updated results from the two trials. Methods Premenopausal women were randomly assigned to receive 5 years of tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression in SOFT and to receive tamoxifen plus ovarian suppression or exemestane plus ovarian suppression in TEXT. Randomization was stratified according to the receipt of chemotherapy. Results In SOFT, the 8-year disease-free survival rate was 78.9% with tamoxifen alone, 83.2% with tamoxifen plus ovarian suppression,...
385 citations
••
TL;DR: The detailed phase diagram of the layered P2-Na(x)VO(2) system determined from electrochemical intercalation/deintercalation in sodium batteries and in situ X-ray diffraction experiments shows that four main single-phase domains exist within the 0.5≤x≤0.9 range.
Abstract: Layered oxides are important as electrode materials for batteries and because of the strong electronic correlations resulting from their unique structure. Electrochemical investigations of the layered P2-NaxVO2 system in sodium batteries together with in situ X-ray diffraction experiments now result in the elucidation of the room-temperature phase diagram of this system.
384 citations
Authors
Showing all 28995 results
Name | H-index | Papers | Citations |
---|---|---|---|
Nicholas G. Martin | 192 | 1770 | 161952 |
George F. Koob | 171 | 935 | 112521 |
Daniel J. Jacob | 162 | 656 | 76530 |
Arthur W. Toga | 159 | 1184 | 109343 |
James M. Tour | 143 | 859 | 91364 |
Floyd E. Bloom | 139 | 616 | 72641 |
Herbert Y. Meltzer | 137 | 1148 | 81371 |
Jean-Marie Tarascon | 136 | 853 | 137673 |
Stanley Nattel | 132 | 778 | 65700 |
Michel Haïssaguerre | 117 | 757 | 62284 |
Liquan Chen | 111 | 689 | 44229 |
Marion Leboyer | 110 | 773 | 50767 |
Jean-François Dartigues | 106 | 631 | 46682 |
Alexa S. Beiser | 106 | 366 | 47457 |
Robert Dantzer | 105 | 497 | 46554 |